Found: 5
Select item for more details and to access through your institution.
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy.
- Published in:
- Prostate, 2022, v. 82, n. 14, p. 1406, doi. 10.1002/pros.24414
- By:
- Publication type:
- Article
Early biochemical and radiographic response after one cycle of [<sup>177</sup>Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 12, p. 3765, doi. 10.1007/s00259-023-06326-w
- By:
- Publication type:
- Article
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4727, doi. 10.1007/s00259-022-05910-w
- By:
- Publication type:
- Article
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-up.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 12, p. 4262, doi. 10.1007/s00259-022-05853-2
- By:
- Publication type:
- Article
Matched-pair analysis of [<sup>177</sup>Lu]Lu-PSMA I&T and [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 9, p. 3269, doi. 10.1007/s00259-022-05744-6
- By:
- Publication type:
- Article